Ibrutinib monotherapy in relapsed or refractory, transformed diffuse large B-cell lymphoma

BACKGROUND: Histological transformation to diffuse large B-cell lymphoma (tDLBCL) occurs in a significant proportion of indolent lymphomas. However, few studies of novel agents inform its management, particularly when relapsed after or refractory (R/R) to prior treatment. PATIENTS AND METHODS: We pr...

詳細記述

保存先:
書誌詳細
出版年:Clin Lymphoma Myeloma Leuk
主要な著者: Graf, Solomon A., Cassaday, Ryan D., Morris, Karolyn, Voutsinas, Jenna M., Wu, Qian Vicky, Behnia, Sanaz, Lynch, Ryan C., Krakow, Elizabeth, Rasmussen, Heather, Chauncey, Thomas R., Kanan, Sandra, Soma, Lorinda, Smith, Stephen D., Gopal, Ajay K.
フォーマット: Artigo
言語:Inglês
出版事項: 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7904587/
https://ncbi.nlm.nih.gov/pubmed/33358575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2020.11.023
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料